176 related articles for article (PubMed ID: 37860180)
1. Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Li H; Long G; Tian J
Front Oncol; 2023; 13():1255632. PubMed ID: 37860180
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
Del Giudice F; Asero V; Bologna E; Scornajenghi CM; Carino D; Dolci V; Viscuso P; Salciccia S; Sciarra A; D'Andrea D; Pradere B; Moschini M; Mari A; Albisinni S; Krajewski W; Szydełko T; Małkiewicz B; Nowak Ł; Laukhtina E; Gallioli A; Mertens LS; Marcq G; Cimadamore A; Afferi L; Soria F; Mori K; Tully KH; Pichler R; Ferro M; Tataru OS; Autorino R; Crivellaro S; Crocetto F; Busetto GM; Basran S; Eisenberg ML; Chung BI; De Berardinis E
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046598
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
Kulkarni GS; Lilge L; Nesbitt M; Dumoulin-White RJ; Mandel A; Jewett MAS
Eur Urol Open Sci; 2022 Jul; 41():105-111. PubMed ID: 35813250
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
[TBL] [Abstract][Full Text] [Related]
6. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
7. Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; von Deimling M; Bianchi A; Pallauf M; Majdoub M; Pradere B; Abufaraj M; Moschini M; Karakiewicz PI; Iwatani K; Miki J; Kimura T; Shariat SF
BJU Int; 2023 Jun; 131(6):643-659. PubMed ID: 36479820
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
[TBL] [Abstract][Full Text] [Related]
9. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
Chen S; Zhang N; Shao J; Wang X
Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
[TBL] [Abstract][Full Text] [Related]
10. Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.
Huang D; Jin YH; Weng H; Huang Q; Zeng XT; Wang XH
Front Oncol; 2019; 9():121. PubMed ID: 30881921
[No Abstract] [Full Text] [Related]
11. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
[TBL] [Abstract][Full Text] [Related]
16. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
17. Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.
Lee LS; Thong PS; Olivo M; Chin WW; Ramaswamy B; Kho KW; Lim PL; Lau WK
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):213-20. PubMed ID: 21112542
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.
Rodrigues Pessoa R; Mueller AC; Boxley P; Flaig TW; Piper C; Konety B; Yu JB; Gershman B; Kukreja J; Kim SP
Urol Oncol; 2021 Nov; 39(11):786.e1-786.e8. PubMed ID: 33846085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]